Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central
Privacy Policy
|
 |
-
Effects of long-term treatment
with suloctidil on blood viscosity, erythrocyte deformability and total
fibrinogen plasma levels in diabetic
patients.
Roncucci R, De Hertogh R, Dormandy JA,
Doumont J, Gurewich V, Lambelin G, Lansen J, Rottiers R, Souridis E, Van
Stalle F, Versee
L.
1-(4-Isopropylthiophenyl)-2-n-octylaminopropanol
(suloctidil, Sulocton), a drug introduced into clinical practice for the
treatment of cerebral and peripheral vascular insufficiency and its
complications, has been shown to decrease blood hyperviscosity after
long-term treatment in diabetic patients. Suloctidil was particularly
effective in lowering measured blood viscosity at high shear rate (230
s-1). At low shear rate (0.77 s-1) a decreasing effect was also observed
but reached a statistically significant level only after one month.
Since neither total plasma fibrinogen levels nor red blood cell
deformability were modified by suloctidil treatment, its lowering effect
on blood hyperviscosity could be due to a hitherto unrecognized
mechansim of action.
Publication Types:
- Clinical Trial
- Randomized Controlled Trial
PMID: 582768 [PubMed -
indexed for MEDLINE]
|